{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:18:11Z","timestamp":1789114691411,"version":"build-2803163510"},"reference-count":94,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2012,11,4]],"date-time":"2012-11-04T00:00:00Z","timestamp":1351987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Drug Discovery"],"published-print":{"date-parts":[[2013,1,1]]},"DOI":"10.1517\/17460441.2013.738193","type":"journal-article","created":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T01:25:03Z","timestamp":1352078703000},"page":"93-103","source":"Crossref","is-referenced-by-count":26,"title":["The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania"],"prefix":"10.1517","volume":"8","author":[{"given":"Frank I","family":"Tarazi","sequence":"first","affiliation":[{"name":"Harvard Medical School and McLean Hospital, Department of Psychiatry and Neuroscience","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo C","family":"Neill","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2012,11,4]]},"reference":[{"key":"e_1_3_1_3_1","unstructured":"Product Information Saphris\u00ae (asenapine) sublingual tablets. Initial US approval: 2009"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2009.45.12.1421561"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.712114"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31823f872f"},{"key":"e_1_3_1_7_1","volume-title":"161st Amer Psychiatric Assoc","author":"Peeters PAM","year":"2008","unstructured":"Peeters PAM , Bockbrader H , Spaans E , Asenapine pharmacokinetics: influence of hepatic and renal impairment [Abst NR4-081]. 161st Amer Psychiatric Assoc; 3 \u2013 8 May; Washington DC; 2008"},{"key":"e_1_3_1_8_1","first-page":"1297","article-title":"Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine, quetiapine, or placebo administration on QTc prolongation","volume":"49","author":"Chapel S","year":"2009","unstructured":"Chapel S , Hutmatcher M , Haig G , Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine, quetiapine, or placebo administration on QTc prolongation. J Clin Psychopharmacol 2009; 49: 1297- 308","journal-title":"J Clin Psychopharmacol"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107082944"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2003.09.010"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0214"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2008.11.001"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(24)38019-X"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(00)00119-6"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(01)00312-8"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.087163"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2008.20"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.08.019"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.07.015"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(98)00078-1"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(03)00792-4"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2003.02239.x"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-007-0973-y"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01245232"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0924-977X(95)00056-U"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/1044-7431(92)90030-6"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevNeurobiol.v12.i1-2.20"},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.9.1367"},{"key":"e_1_3_1_29_1","first-page":"461","volume-title":"Goodman and Gilman's the pharmacological basis of therapeutics","author":"Baldessarini RJ","year":"2005","unstructured":"Baldessarini RJ , Tarazi FI . Pharmacotherapy of psychosis and mania. In: Brunton LL , Lazo JS , Parker KL , editors. Goodman and Gilman's the pharmacological basis of therapeutics. 11th edition. McGraw-Hill; New York; 2005. p. 461- 500","edition":"11"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-008-1098-7"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(97)00046-8"},{"key":"e_1_3_1_32_1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0022-3565(24)29589-6","article-title":"Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment","volume":"297","author":"Tarazi FI","year":"2001","unstructured":"Tarazi FI , Zhang K , Baldessarini RJ . Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2001; 297: 711- 17","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-1793-y"},{"key":"e_1_3_1_34_1","volume-title":"160th Amer Psychiatric Assoc","author":"Fleming K","year":"2007","unstructured":"Fleming K , Potkin SG , Binneman B , Asenapine improves cognitive function in acute schizophrenia: A placebo- and risperidone-controlled trial [Abst NR513]. 160th Amer Psychiatric Assoc; 19 \u201324 May; San Diego, CA; 2007"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(93)90104-2"},{"key":"e_1_3_1_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244112"},{"key":"e_1_3_1_37_1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0022-3565(24)36475-4","article-title":"Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs","volume":"280","author":"Florijn WJ","year":"1997","unstructured":"Florijn WJ , Tarazi FI , Creese I . Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J Pharmacol Exp Ther 1997; 280: 561- 9","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_1_38_1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0022-3565(24)37099-5","article-title":"Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs","volume":"283","author":"Lidow MS","year":"1997","unstructured":"Lidow MS , Goldman-Rakic PS . Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. J Pharmacol Exp Ther 1997; 283: 939- 46","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(92)90242-R"},{"key":"e_1_3_1_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108095704"},{"key":"e_1_3_1_41_1","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/S0022-3565(25)10140-7","article-title":"Chronic clozapine treatment decreases 5-hydroxytryptamine1C receptor density in the rat choroid plexus: comparison with haloperidol","volume":"264","author":"Kuoppamaki M","year":"1993","unstructured":"Kuoppamaki M , Seppala T , Syvalahti E , Chronic clozapine treatment decreases 5-hydroxytryptamine1C receptor density in the rat choroid plexus: comparison with haloperidol. J Pharmacol Exp Ther 1993; 264: 1262- 7","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_1_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1016-3"},{"key":"e_1_3_1_43_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2999-05.2005"},{"key":"e_1_3_1_44_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216010-00003"},{"key":"e_1_3_1_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181d35d6b"},{"key":"e_1_3_1_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(96)00062-0"},{"key":"e_1_3_1_47_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)29304-6","article-title":"Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine2C receptor","volume":"299","author":"Rauser L","year":"2001","unstructured":"Rauser L , Savage JE , Meltzer HY , Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine2C receptor. J Pharmacol Exp Ther 2001; 299: 83- 9","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_1_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.12.003"},{"key":"e_1_3_1_49_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1004"},{"key":"e_1_3_1_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/syn.20618"},{"key":"e_1_3_1_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(99)00046-6"},{"key":"e_1_3_1_52_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.41.1.237"},{"key":"e_1_3_1_53_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145709990824"},{"key":"e_1_3_1_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2003.09.009"},{"key":"e_1_3_1_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1724-3"},{"key":"e_1_3_1_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2008.05711.x"},{"key":"e_1_3_1_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/1056-8719(94)90069-8"},{"key":"e_1_3_1_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-7634(99)00037-8"},{"key":"e_1_3_1_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-3589(08)57010-4"},{"key":"e_1_3_1_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-009-1570-z"},{"key":"e_1_3_1_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2010_61"},{"key":"e_1_3_1_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130100811"},{"key":"e_1_3_1_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301015"},{"key":"e_1_3_1_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(86)90203-0"},{"key":"e_1_3_1_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(01)00261-5"},{"key":"e_1_3_1_66_1","volume-title":"Anhedonia and affect deficit states","author":"Klein D","year":"1984","unstructured":"Klein D . Depression and anhedonia. In: Clark C , Fawcett J , editors. Anhedonia and affect deficit states. PMA Publishing; New York, NY: 1984"},{"key":"e_1_3_1_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00697-4"},{"key":"e_1_3_1_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.10340"},{"key":"e_1_3_1_69_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988110001400106"},{"key":"e_1_3_1_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050456"},{"key":"e_1_3_1_71_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110376684"},{"key":"e_1_3_1_72_1","doi-asserted-by":"publisher","DOI":"10.2515\/therapie:2005065"},{"key":"e_1_3_1_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.13"},{"key":"e_1_3_1_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-11-101"},{"key":"e_1_3_1_75_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.164.7.1061"},{"key":"e_1_3_1_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbq038"},{"key":"e_1_3_1_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2010.07.004"},{"key":"e_1_3_1_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-010-2091-5"},{"key":"e_1_3_1_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-008-1364-8"},{"key":"e_1_3_1_80_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.20-11-04320.2000"},{"key":"e_1_3_1_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(98)00156-X"},{"key":"e_1_3_1_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.02.303"},{"key":"e_1_3_1_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2008.06.005"},{"key":"e_1_3_1_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.08.026"},{"key":"e_1_3_1_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2010.05.043"},{"key":"e_1_3_1_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2008.03.018"},{"key":"e_1_3_1_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2011.02.007"},{"key":"e_1_3_1_88_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145710000659"},{"key":"e_1_3_1_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-009-1702-5"},{"key":"e_1_3_1_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2009.01.009"},{"key":"e_1_3_1_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2009.03.012"},{"key":"e_1_3_1_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2009.01.009"},{"key":"e_1_3_1_93_1","doi-asserted-by":"publisher","DOI":"10.2165\/11530280-000000000-00000"},{"key":"e_1_3_1_94_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.1.131"},{"key":"e_1_3_1_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/374542a0"},{"key":"e_1_3_1_96_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900017089"}],"container-title":["Expert Opinion on Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/17460441.2013.738193","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1517\/17460441.2013.738193","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/17460441.2013.738193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:22:53Z","timestamp":1789111373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/17460441.2013.738193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,4]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1,1]]}},"alternative-id":["10.1517\/17460441.2013.738193"],"URL":"https:\/\/doi.org\/10.1517\/17460441.2013.738193","relation":{},"ISSN":["1746-0441","1746-045X"],"issn-type":[{"value":"1746-0441","type":"print"},{"value":"1746-045X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,4]]}}}